Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma

NCT01021423 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01021423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01021423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Terminated
Start date
April 1, 2010
Completion date
March 1, 2011
Enrollment
9 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma, non-hodgkin's lymphoma